{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Once+Weekly&page=24", "query": { "intervention": "Placebo Once Weekly", "page": 24 }, "page_size": 10 }, "pagination": { "page": 24, "page_size": 10, "total_count": 901, "total_pages": 91, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Once+Weekly&page=25&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Once+Weekly&page=23&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T08:12:49.900Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06065540", "title": "A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Cagrilintide", "type": "DRUG" }, { "name": "Semaglutide", "type": "DRUG" }, { "name": "Placebo cagrilintide", "type": "DRUG" }, { "name": "Placebo semaglutide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2734, "start_date": "2023-09-27", "completion_date": "2026-01-06", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-11-15T08:12:49.900Z", "location_count": 100, "location_summary": "Birmingham, Alabama • Pelham, Alabama • Phoenix, Arizona + 79 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Pelham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06065540" }, { "nct_id": "NCT02229396", "title": "Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "Exantide with Dapagliflozin", "type": "DRUG" }, { "name": "Exentide", "type": "DRUG" }, { "name": "Dapagliflozin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 695, "start_date": "2014-09-04", "completion_date": "2017-12-28", "has_results": true, "last_update_posted_date": "2018-12-31", "last_synced_at": "2026-11-15T08:12:49.900Z", "location_count": 76, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Tuscumbia, Alabama + 61 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Tuscumbia", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02229396" }, { "nct_id": "NCT02911285", "title": "NAC for Treating Comorbid PTSD and SUD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Posttraumatic Stress Disorder (PTSD)", "Alcohol Use Disorder (AUD)", "Substance Use Disorder (SUD)" ], "interventions": [ { "name": "N-acetylcysteine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cognitive behavioral therapy", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 90, "start_date": "2016-10", "completion_date": "2019-11-04", "has_results": true, "last_update_posted_date": "2021-05-19", "last_synced_at": "2026-11-15T08:12:49.900Z", "location_count": 2, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02911285" }, { "nct_id": "NCT07409272", "title": "A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Cancer", "Metastatic Pancreatic Cancer", "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Setidegrasib", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "liposomal irinotecan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 614, "start_date": "2026-02-17", "completion_date": "2029-08-31", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-15T08:12:49.900Z", "location_count": 54, "location_summary": "Gilbert, Arizona • Tucson, Arizona • Fort Smith, Arkansas + 47 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07409272" }, { "nct_id": "NCT01142700", "title": "A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C Virus Genotype 1" ], "interventions": [ { "name": "BMS-824393", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Peginterferon Alpha-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2010-07", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2011-03-15", "last_synced_at": "2026-11-15T08:12:49.900Z", "location_count": 11, "location_summary": "Coronado, California • San Diego, California • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "Coronado", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01142700" }, { "nct_id": "NCT04657003", "title": "A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes", "Overweight", "Obesity" ], "interventions": [ { "name": "Tirzepatide", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 938, "start_date": "2021-03-29", "completion_date": "2023-04-10", "has_results": true, "last_update_posted_date": "2024-04-08", "last_synced_at": "2026-11-15T08:12:49.900Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Huntington Park, California + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Huntington Park", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Montclair", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04657003" }, { "nct_id": "NCT00636337", "title": "Inattention in Childhood Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Childhood Cancer" ], "interventions": [ { "name": "Attention Training", "type": "BEHAVIORAL" }, { "name": "Placebo", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "16 Years", "sex": "ALL", "summary": "8 Years to 16 Years" }, "enrollment_count": 23, "start_date": "2007-12", "completion_date": "2012-11", "has_results": false, "last_update_posted_date": "2013-02-18", "last_synced_at": "2026-11-15T08:12:49.900Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00636337" }, { "nct_id": "NCT06131372", "title": "A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Kidney Disease", "Type 2 Diabetes", "Obesity" ], "interventions": [ { "name": "Cagrilintide", "type": "DRUG" }, { "name": "Semaglutide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 626, "start_date": "2024-04-01", "completion_date": "2025-11-06", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-11-15T08:12:49.900Z", "location_count": 25, "location_summary": "Concord, California • Fresno, California • Palm Springs, California + 22 more", "locations": [ { "city": "Concord", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "San Dimas", "state": "California" }, { "city": "San Ramon", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06131372" }, { "nct_id": "NCT01396239", "title": "Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Duchenne Muscular Dystrophy" ], "interventions": [ { "name": "AVI-4658 (Eteplirsen)", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Sarepta Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": "13 Years", "sex": "MALE", "summary": "7 Years to 13 Years · Male only" }, "enrollment_count": 12, "start_date": "2011-07", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2020-03-30", "last_synced_at": "2026-11-15T08:12:49.900Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01396239" }, { "nct_id": "NCT02808585", "title": "Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "PB1046 Injection", "type": "DRUG" }, { "name": "Placebo Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PhaseBio Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2016-06", "completion_date": "2017-12-06", "has_results": true, "last_update_posted_date": "2022-07-14", "last_synced_at": "2026-11-15T08:12:49.900Z", "location_count": 5, "location_summary": "Anniston, Alabama • Peoria, Arizona • Daytona Beach, Florida + 2 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Daytona Beach", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "McKinney", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02808585" } ] }